Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16 studies found for:    hofmeister
Show Display Options
Rank Status Study
1 Active, not recruiting AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Other: Pharmacodynamic Studies;   Other: Fatigue Inventory;   Other: Pharmacogenomic studies;   Drug: AR-42
2 Unknown  Vaccine Therapy in Treating Patients Who Have Undergone Autologous Stem Cell Transplant for High-Risk Lymphoma or Multiple Myeloma
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Small Intestine Cancer
Interventions: Biological: Streptococcus pneumoniae;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
3 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
4 Suspended Wild-type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Biological: Wild-type Reovirus
5 Completed Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Refractory Plasma Cell Myeloma
Interventions: Other: Diagnostic Laboratory Biomarker Analysis;   Biological: Wild-type Reovirus
6 Completed Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: lenalidomide;   Drug: temsirolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Completed Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Procedure: cryotherapy;   Other: questionnaire administration;   Other: pharmacological study
8 Completed Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
Condition: Graft-Versus-Host Disease
Intervention: Drug: Infliximab
9 Completed Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
Condition: Graft-Versus-Host Disease
Intervention: Drug: Pentostatin
10 Completed Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Doxil®;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Arsenic Trioxide
11 Completed Patient-Reported Outcomes With LASIK:PROWL-1
Condition: Laser in Situ Keratomileusis
Intervention:
12 Active, not recruiting Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: lenalidomide;   Drug: vorinostat
13 Completed
Has Results
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Drug: vorinostat;   Other: Correlative studies
14 Recruiting Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: KPT-8602
15 Recruiting Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
16 Recruiting Prospective S&E Study of Wavefront-guided PRK for Myopia With iDesign Advanced Wavescan Studio™ System and Star S4 IR™
Condition: Stable Myopic Refractive Error, With or Without Astigmatism
Intervention: Device: STAR S4 IR laser with iDesign

Indicates status has not been verified in more than two years